{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-036486","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2022-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.796939+00:00","generated_at":"2026-06-20T23:39:43.890842+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Indaptus Therapeutics enters $20M equity purchase agreement with Lincoln Park Capital","bullets":["Lincoln Park committed to buy up to $20M of Indaptus common stock over 36 months (extendable to 48).","Company controls timing of sales; Lincoln Park cannot require purchases or engage in short selling.","Indaptus issued 142,450 initial commitment shares; up to 76,220 additional shares may follow after $10M sold.","Net proceeds will be used for working capital and general corporate purposes.","Agreement includes standard representations, indemnification, and automatic termination on bankruptcy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-036486","json":"https://secwatch.observer/filing/0001493152-22-036486.json","markdown":"https://secwatch.observer/filing/0001493152-22-036486.md","text":"https://secwatch.observer/filing/0001493152-22-036486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222036486/0001493152-22-036486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222036486/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T23:39:43.890842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"737f257287da9e7b7e3b9a0bed58a13553d5778b","claim":"Indaptus Therapeutics, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at Up to $20,000,000 (effective 2022-12-22).","evidence_excerpt":"On December, 22, 2022, Indaptus Therapeutics, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $20.0 million of the Company’s common stock, $0.01 par value per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315222036486/0001493152-22-036486-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Lincoln Park Capital Fund, LLC"},{"label":"Value","value":"Up to $20,000,000"},{"label":"Effective","value":"2022-12-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}